Tobramycin nebuliser solution (TNS) has been investigated in several clinical trials,
including a large, placebo-controlled study that demonstrated efficacy over a 24-week …

BACKGROUND: Inhaled tobramycin has been shown to improve lung function in cystic
fibrosis (CF) patients chronically infected with Pseudomonas aeruginosa. However, to date …

Aerosolized tobramycin has been extensively used in cystic fibrosis (CF) patients in order to
directly deliver the antibiotic to the endobronchial site of infection, and decrease toxicity by …

Chronic infection with Pseudomonas aeruginosa is associated with poor outcomes in
patients with cystic fibrosis (CF). It leads to a reduced quality of life, acceleration of the …

Background and Methods We conducted two multicenter, double-blind, placebo-controlled
trials of intermittent administration of inhaled tobramycin in patients with cystic fibrosis and …

Study objectives To describe the pharmacokinetics and bioavailability of inhaled tobramycin
(TOBI; Chiron Corporation; Seattle, WA), 300-mg dose, delivered by a nebulizer (PARI LC …

Study objectives To determine whether tobramycin solution for inhalation (TSI) can be
administered safely and more efficiently with a new-generation aerosol device, the …

European consensus guidelines recommend nebulised antibiotics for maintenance therapy
in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection. Two …

Background: The cost effectiveness of inhaled TOBIR tobramycin nebuliser solution (TNS) in
CF and chronic pulmonary Pseudomonas aeruginosa infection has been shown in US but …

The long‐term efficacy and safety of aminoglycoside aerosol therapy for Pseudomonas
aeruginosa colonization/infection in cystic fibrosis has not been fully investigated. In the …